SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Exploring the Quick Brown Fox: A Unique Journey
- Exploring Innovative Strategies for Effective Communication
- Understanding the Quick Brown Fox: An Innovative Approach
- Celebrating 25 Years of Unity: Macao's Journey with China
- Discover THREE's Innovative Skincare Breakthroughs Today!
- Novo Nordisk's Strategic Acquisition of Catalent's Manufacturing Assets
- Catalent and Novo Holdings Set to Finalize Major Deal Soon
- Opportunity for Wolfspeed Investors to Pursue Class Action
- Kyverna Therapeutics Investors Alert Over Recent Class Action
- Marqeta Inc. SEC Class Action Lawsuit: What Investors Need to Know
- Urgent Alert for Symbotic Investors Regarding Class Action
- Investors Reminded of Key Deadline in PACS Group Lawsuits
- Crucial Update for Five9 Investors: Lawsuit Deadline Approaching
- Important Update for Rentokil Investors on Class Action Lawsuit
- Important Update for Match Group Investors: Legal Actions Ahead
- Investors Urged to Act in Zeta Global Class Action Case
- Celsius Holdings Investors: Important Litigation Updates
- ASML Holding Class Action: Important Update for Investors
- Deadline Approaches for Hasbro Shareholders in Class Action
- Critical Update for Toronto-Dominion Bank Investors in Class Action
- Investors of Kyverna Therapeutics Can Pursue Class Action
- Xi Jinping Supports Hong Kong's Economic Strategies and Development
- Solar Alliance Energy Gains Shareholder Approval in Key Meeting
- Fruit Street Health Enhances Diabetes Prevention with Meals
- CNOOC Limited Partners with INEOS Energy in New Agreement
- Exciting Collaboration: Celebrate Japan's Fruit Culture
- Investors Urged to Act Before Deadline in Xiao-I Class Action
- Karma Sauce Applauds First We Feast's Bold New Direction
- Cassava Sciences Investors Encouraged to Act on Stock Losses
- Investors Warned of Upcoming Deadline in WM Technology Case
- Investors Urged to Act: Acadia Healthcare Class Action Deadline
- Aehr Test Systems Faces Class Action, Investors Urged to Act Soon
- Investors Alert: Upcoming Lead Plaintiff Motion Deadline for CUBI
- Legal Action Announced for Five9, Inc. Investors Following Stock Decline
- Legal Action Launched for Kyverna Therapeutics Investors
- Everlight Solar's Culture: A Testament to Team Camaraderie and Growth
- Haloid Enhances Safety in Film Productions with Reviews
- Insights on the Growing Demand for Edible Coatings in Produce
- Prospect Ridge Resources Adjusts Plans for Upcoming Meeting
- Legal Update: Toronto-Dominion Bank Securities Class Action
- Key Updates from Nasdaq on the Nasdaq-100 Index Changes
- TeraBox Revolutionizes File Sharing with Free Unlimited Service
- Kessler Topaz Takes Action Against Enphase Energy for Fraud
- Demesne Resources Completes Second Tranche of Financing
- Spiro Celebrated as One of the Top Agencies in Marketing
- Global Uranium Corp. Launches Strategic Marketing Efforts
- UnitedHealth Group Clarifies Misconceptions and Updates Claims
- Neurocrine Biosciences Unveils Potential of CRENESSITY™ for CAH
- Acadia Healthcare Investors Urged to Take Action on Lawsuit
- Global Uranium Corp. Unveils C$1.5 Million Flow-Through Offering